Carglumic Acid Production Cost Reports

The report provides a detailed analysis essential for establishing a carglumic acid production plant. It encompasses all critical aspects necessary for carglumic acid production, including the cost of carglumic acid production, carglumic acid plant cost, carglumic acid production costs, and the overall carglumic acid production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a carglumic acid production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Carglumic Acid (N-carbamoyl-L-glutamic acid) is a specialised pharmaceutical compound that is mainly used in the treatment of rare metabolic disorders. It is primarily used as an orphan drug for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. It is mainly prescribed for managing high levels of ammonia in the blood, especially in patients with a deficiency of N-acetylglutamate synthase enzyme. It works by supporting the normal metabolic function of the urea cycle, which helps the body remove excess ammonia and prevent serious neurological complications. It is also used in certain cases of organic acidemia to support the body’s ability to remove excess ammonia. Moreover, it plays an important role in pediatric care, as many of these disorders are diagnosed in newborns and young children. It is often used in hospitals and clinical settings for emergency and long-term therapy in patients with inherited urea cycle disorders.

The market for carglumic acid is primarily driven by its demand as a drug for the treatment of specific metabolic disorders, especially conditions related to high ammonia levels in the blood. Its application for the treatment of acute hyperammonaemia in patients with a deficiency in N-acetyl glutamate synthase largely drives its demand in the medical and pharmaceutical industries. Its application in managing hyperammonemia in patients caused by enzyme deficiencies by restoring normal metabolic function further supports its demand in the healthcare sector.

Its demand as an essential drug in the medical research and biotechnology industries for supporting the development of therapies for rare genetic metabolic diseases also supports its market growth. Furthermore, advancements in drug formulation, supplier reliability, sustainable production practices, and efficient global distribution networks play a major role in shaping industrial carglumic acid procurement and supporting its market globally. Additionally, its procurement decisions also depend on factors, including the cost and availability of raw materials, strict regulatory compliance for orphan drug production, and quality standards in pharmaceutical production.

Raw Material for Carglumic Acid Production

According to the carglumic acid production plant project report, the major raw materials for carglumic acid production include L-glutamic acid, hydrochloric acid, and potassium cyanate.

Production Process of Carglumic Acid

The extensive carglumic acid production cost report consists of the following industrial production process:

1. Production via Chemical Synthesis: The production process of carglumic acid begins with dissolving L-glutamic acid in water, followed by acidification using hydrochloric acid to prepare the reaction medium. Then, potassium cyanate is added to the solution, and the mixture is heated with continuous stirring for several hours to allow the carbamoylation reaction to take place. After the reaction is complete, the mixture is cooled to room temperature and left to evaporate slowly, which leads to the formation of a white solid. Further, the crude product is purified by slow evaporation of its ethanol solution, which results in the formation of crystals of carglumic acid as the final product.

Carglumic acid is a synthetic structural analogue of N-acetylglutamate (NAG) that functions as a carbamoyl phosphate synthetase 1 (CPS1) activator. It appears as a white to off-white crystalline solid. The molecular formula of the compound is C6H10N2O5, and its molar mass is 190.15 g/mol. It is commercially sold under its trade name, Carbaglu. Its density is approximately 1.50 g/cm³, and its melting point is around 174 °C. The boiling point of the compound is approximately 438.1 °C, and its flash point is around 218.8 °C. It is soluble in boiling water and slightly soluble in cold water, DMSO, and methanol, but is practically insoluble in most organic solvents. It is recommended to store the compound at 2–8 °C under an inert atmosphere and protected from light to maintain its stability. The compound is classified as harmful if swallowed and may cause skin irritation, serious eye irritation, and respiratory tract irritation upon exposure. It is recommended to wear protective gloves, a dust mask (type N95), and eye protection while handling the substance. Extended or improper exposure to this compound may lead to adverse effects, and therefore appropriate precautionary measures should always be followed during its handling and use.